QuidelOrtho Appoints Erich Wolff as Executive VP to Enhance Strategic Leadership

QuidelOrtho Strengthens Leadership with New Executive Appointment

QuidelOrtho Corporation, a prominent figure in the in vitro diagnostics sector, enhances its strategic leadership with the appointment of Erich Wolff as Executive Vice President of Strategy & Corporate Development. In this pivotal role, Wolff reports directly to President and CEO Brian Blaser and is responsible for steering the company's enterprise strategy, business development initiatives, government affairs, and portfolio management. His extensive background in the healthcare and diagnostics industries, spanning over two decades, positions him well to drive QuidelOrtho's ambitions for growth and innovation.

Wolff's previous experience includes significant leadership roles at renowned companies such as Medtronic and BD, where he showcased his expertise in strategy and mergers and acquisitions. At Medtronic, he was instrumental in revitalizing the global diabetes business and overseeing corporate development for its neurosciences and diabetes divisions, cumulatively valued at $11.5 billion. His tenure at BD included key contributions to the spinoff of Embecta and the acquisition of Parata Systems, demonstrating his ability to navigate complex corporate transformations. Blaser commends Wolff’s strategic vision and operational acumen, emphasizing how these attributes will play a critical role in shaping QuidelOrtho's future as it seeks to innovate and lead in the diagnostics field.

Wolff expresses enthusiasm about joining QuidelOrtho, recognizing the company’s strong global presence and dedication to innovation in diagnostics. He looks forward to collaborating closely with the leadership team to formulate and implement strategies that not only drive growth but also deliver long-term value to stakeholders. His onboarding signals a strategic move by QuidelOrtho as it positions itself for further advancements in a competitive market, focusing on enhancing diagnostic solutions worldwide.

In addition to Wolff's appointment, QuidelOrtho continues to prioritize innovation within its portfolio, enhancing its capabilities in in vitro diagnostics. The company’s commitment to improving healthcare outcomes through advanced diagnostic solutions remains a core tenet of its operations. With a strong leadership team and a clear strategic direction, QuidelOrtho is well-equipped to navigate the complexities of the diagnostic landscape.

As the company embarks on this new chapter, it aims to leverage Wolff's expertise to not just expand its market reach but also to foster collaborations that enhance diagnostic technologies and methodologies, ensuring it remains at the forefront of the industry.